The Mirage microfiber sirolimus eluting coronary scaffold

Teguh Santoso Sukamto, Liew Houng Bang, Ricardo Costa, Daniel Chamié, Solomon Su, Alexander Abizaid, Yoshinobu Onuma, Patrick W.J.C. Serruys

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Bioresorbable scaffolds (BRSs) may potentially overcome the many pitfalls related to drug eluting stents (DESs). Following CE mark approval, the rapid adoption of this novel treatment has led to its use in all comers with complex lesion morphology even without randomized comparison with the DESs. The only published randomized clinical study thus far is the ABSORB II. However, the current generation (ABBOTT Bioresorbable Vascular Scaffold, BVS™) still has a lot of limitations. The Mirage Microfiber Sirolimus Eluting Coronary Scaffold (MMSES™, Manli Cardiology™) is designed to address the concerns of BVSs, such as improved vessel wall conformability, reduced strut protrusion into lumen, fracture resistance allowing rapid deployment until rated burst pressure, excellent deliverability, faster degradation time, ability to store at ambient room temperature <25°C, and no restriction on size availability. In contrast to the BVSs, the MMSES struts are round and thinner with less protrusion into the lumen. This streamlined geometry results in lesser activation of coagulation cascade and better promotion of endothelialization. This feature is interesting, especially in view of recent reports of somewhat higher BVSs thrombosis as compared to DESs.

Original languageEnglish
Title of host publicationBioresorbable Scaffolds
Subtitle of host publicationFrom Basic Concept to Clinical Applications
PublisherCRC Press
Pages316-318
Number of pages3
ISBN (Electronic)9781498779777
ISBN (Print)9781498779746
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint Dive into the research topics of 'The Mirage microfiber sirolimus eluting coronary scaffold'. Together they form a unique fingerprint.

Cite this